• About Us
    • Contact Us
    • Login
    • ObGFirst
  • COVID-19
  • Alerts
  • OB
  • 2T US Atlas
  • The Genome
  • GYN
    • GYN
    • Sexual Health
  • Primary Care
  • Your Practice
  • GrandRounds
  • My Bookshelf
  • Now@ObG
  • Media
About Us Contact Us Login ObGFirst
  • COVID-19
  • Alerts
  • OB
  • 2T US Atlas
  • The Genome
  • GYN
    • GYN
    • Sexual Health
  • Primary Care
  • Your Practice
  • GrandRounds
  • My Bookshelf
  • Now@ObG
  • Media
Grand Rounds

Subclinical Hypothyroidism and Pregnancy Outcome – Is There a Relationship?

image_pdfFavoriteLoadingFavorite

BACKGROUND AND PURPOSE:

  • Overt thyroid disease complicates 4% of pregnancy and is associated with adverse outcomes
  • Little is known regarding the relationship between subclinical hypothyroidism (SCH) or thyroid autoimmunity and adverse pregnancy outcomes
  • Plowden et al. (AJOG, 2017) examined whether there is an association between prepregnancy anti-thyroid antibodies/subclinical hypothyroidism and obstetric complications

METHODS:

  • Secondary analysis of prospective cohort study from the Effects of Aspirin in Gestation and Reproduction (EAGeR) trial, a multicenter, double-blind, RCT on the effect of low-dose aspirin on live birth
    • 18-40 year-old women
    • 1-2 previous pregnancy losses
    • Analysis restricted to women with ongoing pregnancy > 20 weeks
  • Prepregnancy levels of thyroid-stimulating hormone (TSH), free thyroxine fT4), thyroglobulin antibody (anti-TG), and thyroid peroxidase antibody (anti-TPO) were collected
    • Levels adjusted for age and body mass index
  • Participants categorized in to 2 categories: TSH < 2.5 or ≥5 mIU/L
    • While SCH is usually defined as TSH above the normal range (4.5–5.0 mIU/L) with a normal fT4 level the National Academy of Clinical Biochemistry found that 95% of patients without any symptoms of thyroid dysfunction have a TSH level <2.5 mIU/L
  • Adjusted for aspirin use because of association with pregnancy in women with single recent loss
  • Primary outcomes
    • Preterm Birth (PTB), defined as delivery between 20w0d and 26w6d
    • GDM
    • Preeclampsia

RESULTS:

  • Data was pooled from 1193 women
  • There was no association between prepregnancy TSH < 2.5 vs ≥5 mIU/L and PTD, GDM or preeclampsia
  • Among women with thyroid antibodies, there was no association between PTB, GDM or preeclampsia
  • Authors took in to account whether PTB was medically indicated and there was still no association
  • Among women with thyroid autoimmunity, there were no differences in PTB, GDM or preeclampsia including whether stratified by TSH level

CONCLUSION:

  • Previous studies on SCH and preeclampsia show mixed results
    • Previous studies used higher TSH cut-offs and did not adjusted for BMI
  • The results from this study are aligned with previous studies on SCH and GDM
  • This study supports current ACOG recommendations that low-risk asymptomatic women should not be screened routinely for thyroid dysfunction or autoimmunity and patients with SCH and thyroid autoimmunity can be reassured

Learn More – Primary Sources:

Thyroid-stimulating hormone, anti–thyroid antibodies, and pregnancy outcomes

image_pdfFavoriteLoadingFavorite

< Previous
All Grand Rounds Posts
Next >

Related ObG Topics:

How Do Thyroid Levels Impact Life Expectancy?
Infertility Evaluation: Who, When and How
Should Levothyroxine be Used to Treat Subclinical Hypothyroidism?

Sections

  • COVID-19
  • Alerts
  • OB
  • GYN
    • GYN
    • Sexual Health
  • 2T US Atlas
  • The Genome
  • Primary Care
  • Your Practice
  • Grand Rounds
  • My Bookshelf
  • Now@ObG
  • Media

Are you an
ObG Insider?

Get specially curated clinical summaries delivered to your inbox every week for free

  • Site Map/
  • © ObG Project/
  • Terms and Conditions/
  • Privacy/
  • Contact Us/
© ObG Project
SSL Certificate


  • Already an ObGFirst Member?
    Welcome back

    Log In

    Want to sign up?
    Get guideline notifications
    CME Included

    Sign Up

Download Your ObG App
HERE!

Sign In

Lost your password?

Sign Up for ObGFirst and Stay Ahead

  • - Professional guideline notifications
  • - Daily summary of a clinically relevant
    research paper
  • - Includes 1 hour of CME every month

ObGFirst Free Trial

Already a Member of ObGFirst®?

Please log in to ObGFirst to access the 2T US Atlas

Password Trouble?

Not an ObGFirst® Member Yet?

  • - Access 2T US Atlas
  • - Guideline notifications
  • - Daily research paper summaries
  • - And lots more!
ObGFirst Free Trial

Media - Internet

Computer System Requirements

OBG Project CME requires a modern web browser (Internet Explorer 10+, Mozilla Firefox, Apple Safari, Google Chrome, Microsoft Edge). Certain educational activities may require additional software to view multimedia, presentation, or printable versions of their content. These activities will be marked as such and will provide links to the required software. That software may be: Adobe Flash, Apple QuickTime, Adobe Acrobat, Microsoft PowerPoint, Windows Media Player, or Real Networks Real One Player.

Disclosure of Unlabeled Use

This educational activity may contain discussion of published and/or investigational uses of agents that are not indicated by the FDA. The planners of this activity do not recommend the use of any agent outside of the labeled indications.

The opinions expressed in the educational activity are those of the faculty and do not necessarily represent the views of the planners. Please refer to the official prescribing information for each product for discussion of approved indications, contraindications, and warnings.

Disclaimer

Participants have an implied responsibility to use the newly acquired information to enhance patient outcomes and their own professional development. The information
presented in this activity is not meant to serve as a guideline for patient management. Any procedures, medications, or other courses of diagnosis or treatment discussed or suggested in this activity should not be used by clinicians without evaluation of their patient’s conditions and possible contraindications and/or dangers in use, review of any applicable manufacturer’s product information, and comparison with recommendations of other authorities.

Jointly provided by

NOT ENOUGH CME HOURS

It appears you don't have enough CME Hours to take this Post-Test. Feel free to buy additional CME hours or upgrade your current CME subscription plan

Subscribe

JOIN OBGFIRST AND GET CME/CE CREDITS

One of the benefits of an ObGFirst subscription is the ability to earn CME/CE credits from the ObG entries you read. Tap the button to learn more about ObGFirst

Learn More
Leaving ObG Website

You are now leaving the ObG website and on your way to PRIORITY at UCSF, an independent website. Therefore, we are not responsible for the content or availability of this site